RHOEN-KLINIKUM (ETR:RHK) Stock Upgrade
RHOEN-KLINIKUM (ETR:RHK) shares were lifted by analysts at Jefferies & Company Inc. to a solid Buy rating in an analyst research report sent to clients and investors today. Analysts now have a EUR 31.40 PT on the shares. Jefferies & Company Inc.’s PT gives a possible upside of 14.98%.
From a total of 9 analysts covering RHOEN-KLINIKUM (ETR:RHK) stock, 3 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 33% of the ratings are positive. The highest target price is €30 while the lowest target price is €24.60. The mean of all analyst targets is €28.14 with a 3.11% above today’s (€27.29) stock price. RHOEN-KLINIKUM was the topic of 23 analyst reports since August 6, 2015 according to the firm StockzIntelligence Inc. Bankhaus Lampe upgraded shares on December 1 to “Buy” rating. Landesbank upgraded shares to “Buy” rating and €29 target share price in a report from a September 12. S&P Research maintained RHK stock in a recent report from November 7 with “Hold” rating. Baader Wertpapierhandelsbank maintained the rating on September 11. Baader Wertpapierhandelsbank has a “Hold” rating and a €27 price target on shares. Finally, Warburg Research maintained the stock with “Hold” rating in a report issued on a November 7.
The stock increased 1.47% or EUR 0.4 on December 16, striking EUR 27.29. Approximately 196,911 shares of stock traded hands or 54.05% up from the average. Rhoen-Klinikum AG (ETR:RHK) has risen 13.49% since May 20, 2015 and is uptrending. It has outperformed by 16.12% the S&P500.
Rhoen Klinikum AG is a Germany-based well-known provider of health care services. The company has a market cap of 1.80 billion EUR. It is primarily engaged in building, acquiring and operating privately owned hospitals. It has 30.61 P/E ratio. The Company’s portfolio comprises basic and standard care, intermediate care, maximum care, specialist care, medical care centers at hospitals, portal clinics, university hospitals and academic teaching hospitals.